Published in Physician Law Weekly, February 8th, 2006
Innovive anticipates commencing phase I trials in the first half of 2006 to study the immunotherapeutic (INNO-305) in the treatment of acute myelogenous leukemia (AML), myelodysplastic syndrome (MDS), non small cell lung cancer (NSCLC) and mesothelioma.
WT1 is expressed in most leukemias and in a variety of solid tumors. WT1 expression is a known indicator of poor outcome in acute leukemia.
INNO-305 is unique among WT1 peptide cancer immunotherapeutics...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Physician Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.